# US 2008/0075723 A1 · Endotheliase 2 ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0075723 A1
- Document ID: US20080075723A1
- Status: Published application
- Kind: A1
- Application number: 11/859,178
- Filed: 2007-09-21
- Published: 2008-03-27
- Earliest claimed: 2003-08-14
- Assignees: Dyax Corp., a Massachusetts corporation
- Inventors: Andrew NIXON; Edwin MADISON
- Web page: https://patentgrep.com/patent/US20080075723A1

## CPC

- C07K 16/40: against enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/06: Antipsoriatics
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Proteins that bind to ET2, such as immunoglobulins that inhibit ET2 with high affinity and selectivity, are provided. The ET2 binding proteins can be used to treat a variety of disorders, including angiogenesis-associated disorders.

## Claims

### Claim 1

An isolated protein comprising a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein
(1) the first and second immunoglobulin variable domain sequences form an antigen binding site that specifically binds to human Endotheliase-2 (ET2); and
(2) the protein has one or more of the following characteristics:
(a) the protein inhibits ET2 with an inhibition constant (Ki) of less than 300 nM;
(b) the HC immunoglobulin variable domain sequence comprises one or more CDRs that are at least 85%, identical to a CDR of a HC variable domain of A10, G3, A6, A7, C8, H9, G10-R2, F3-R2, C6-R2, A4-R3, C1-R3, A2, B5, D2, D5, F8, H10, or C9;
(c) the LC immunoglobulin variable domain sequence comprises one or more CDRs that are at least 85% identical to a CDR of a LC variable domain of A10, G3, A6, A7, C8, H9, G10-R2, F3-R2, C6-R2, A4-R3, C1-R3, A2, B5, D2, D5, F8, H10, or C9;
(d) the LC immunoglobulin variable domain sequence is at least 85% identical to a LC variable domain of A10, G3, A6, A7, C8, H9, G10-R2, F3-R2, C6-R2, A4-R3, C1-R3, A2, B5, D2, D5, F8, H10, or C9;
(e) the HC immunoglobulin variable domain sequence is at least 85% identical to a HC variable domain of A10, G3, A6, A7, C8, H9, G10-R2, F3-R2, C6-R2, A4-R3, C1-R3, A2, B5, D2, D5, F8, H10, or C9; and
(f) the protein binds an epitope that overlaps with an epitope bound by A10, G3, A6, A7, C8, H9, G10-R2, F3-R2, C6-R2, A4-R3, C1-R3, A2, B5, D2, D5, F8, H10, or C9.

### Claim 2 (depends on 1)

The protein of claim 1, wherein the protein binds to the ET2 active site.

### Claim 3 (depends on 1)

The protein of claim 1, wherein the protein inhibits ET2 enzymatic activity.

### Claim 4 (depends on 1)

The protein of claim 1, wherein the protein accumulates at sites of angiogenesis in vivo.

### Claim 5 (depends on 1)

The protein of claim 1, wherein the protein inhibits proteolysis of vessel basement membrane.

### Claim 6 (depends on 1)

The protein of claim 1, wherein the protein inhibits angiogenesis in vitro or in vivo.

### Claim 7 (depends on 1)

The protein of claim 1, wherein the HC and LC variable domain sequences are components of the same polypeptide chain.

### Claim 8 (depends on 1)

The protein of claim 1, wherein the HC and LC variable domain sequences are components of different polypeptide chains.

### Claim 9 (depends on 1)

The protein of claim 1, wherein the protein is a full-length antibody.

### Claim 10 (depends on 1)

The protein of claim 1, wherein the antibody is a human or humanized antibody.

### Claim 11 (depends on 1)

The protein of claim 1, wherein the protein comprises a human antibody framework region.

### Claim 12 (depends on 1)

The protein of claim 1, wherein the protein comprises an Fc domain.

### Claim 13 (depends on 1)

The protein of claim 1, wherein the HC variable domain sequence comprises SEQ ID NO:89 and the LC variable domain sequence comprises SEQ ID NO:90.

### Claim 14 (depends on 1)

The protein of claim 1, wherein the protein reduces tumor growth in a SCID mouse model.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising the protein of claim 1 and a pharmaceutically acceptable carrier.
